er primarily reflect our continuing success in implementing process improvements to strengthen margins in our current API business, as well as changes in the product mix favoring higher margin products," noted Sucheth R. Davuluri, Chief Executive Officer of Neuland Labs
. "In addition to supporting these positive trends, we also intend to continue to invest in marketing and business development activities focused on growing our contract manufacturing business, which we view as central to achieving robust profitable growth going forward."
For a complete set of Neuland's FY 2013 and FY 2012 financial data, visit http://neulandlabs.com/about/financials.html.
Neuland Laboratories is listed on India's National Stock Exchange under the symbol NEULANDLAB and on the Bombay Stock Exchange under code 524558 and the symbol Neuland.EO.
* = Indian rupees
About Neuland Labs
For over 25 years Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in 85 countries. Neuland Labs has developed more than 300 processes and 60 APIs, and it has filed more than 40 US drug master files (DMFs), 10 EU CEPs and a total of more than 400 DMFs worldwide. Its manufacturing facilities are inspected and approved by the US FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the FDA, TGA, EDQM, German Health Authority, ISO 14001, ISO 27001 and OHSAS 18001. For more information, visit www.NeulandLabs.com.Contacts:Neuland Laboratories Ltd.
US MediaNS Viswanathan
BLL Partners/Brandwidth SolutionsVice President- Finance
Barbara Lindheim+91 40 30211600<
Page: 1 2 3 Related biology technology :1
|SOURCE Neuland Laboratories Ltd.|
Copyright©2012 PR Newswire.
All rights reserved
. Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results2
. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs3
. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 20114
. Interleukin Genetics Reports Third Quarter 2011 Financial Results5
. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders6
. Nile Therapeutics Reports 2011 Third Quarter Financial Results7
. Pharmasset Reports Fiscal Year End 2011 Financial Results8
. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 20119
. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results10
. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy11
. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies